Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT02132234

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02132234
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
Poland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02132234. Randomized; triple masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Condition
Rheumatoid Arthritis
Condition
Psoriatic Arthritis
Condition
Ankylosing Spondylitis
Condition
Hypertension
Intervention (Drug)
Etanercept
Intervention (Drug)
Adalimumab
Intervention (Drug)
Certolizumab
Intervention (Drug)
Infliximab
Lead sponsor
Jagiellonian University (class: other)
Collaborator
Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland (class: not stated)

Record details

Record id
cardio:ct-nct02132234
Content hash
55d706b0626edeac325393d738a59d3921fc5f8e4c0d2bd51998aec0bbdd5483